This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Vexim SA
Vexim SA, a pioneering name in the medical device industry, is headquartered in France and operates extensively across Europe. Founded in 2006, the company has established itself as a leader in the development of innovative solutions for spinal surgery, particularly through its flagship product, the SpineJack® system. This unique device is designed to provide minimally invasive treatment for vertebral compression fractures, setting Vexim apart in a competitive market. With a commitment to enhancing patient outcomes, Vexim SA has achieved significant milestones, including regulatory approvals and partnerships that bolster its market position. The company’s focus on research and development ensures that it remains at the forefront of spinal surgery technology, making it a trusted choice among healthcare professionals.
DitchCarbon Score
How does Vexim SA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Vexim SA's score of 42 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Vexim SA, headquartered in France, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Stryker Corporation, which may influence its climate commitments and reporting practices. While Vexim SA has not established its own reduction targets or climate pledges, it inherits sustainability initiatives from Stryker Corporation. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions across its operations. As a subsidiary, Vexim SA's climate strategy may align with Stryker's broader sustainability goals, although specific details on emissions reductions or targets are not available at this time. The company is expected to contribute to the overarching climate commitments set by its parent organisation, reflecting a commitment to environmental responsibility within the medical technology industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | - | - | 00,000,000 |
| Scope 2 | 146,705,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Vexim SA is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
